Trial Profile
A Phase 2 Study of Avelumab in Combination With Bladder-Directed Radiation in Cisplatin-Ineligible Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- 03 May 2023 Planned primary completion date changed from 1 Jun 2023 to 31 Dec 2024.
- 18 Apr 2022 Status changed from active, no longer recruiting to recruiting.
- 14 Sep 2021 Planned primary completion date changed from 31 Jan 2022 to 1 Jun 2023.